Fujitsu: Improving Quality of Life for Cancer Patients with AI Breakthroughs in Genomics

-What challenges do you hope to address in the future as cancer genome medicine continues to evolve?

Dr. Imoto: The Aichi Cancer Center, a comprehensive cancer center that integrates the research institute and the hospital, will continue to provide each patient and their family with the best cancer care at all stages of life, from prevention diagnosis, treatment and post-treatment. Through the hospital, we hope to contribute to the advancement of cancer care in Japan and around the world by making available the results of Aichi Cancer Center’s efforts in early diagnosis, medicine and immunotherapy, and prevention based on genomic information.

In this context, we believe that the effective use of AI technology will advance the average quality of cancer care and lead to optimal personalized cancer care for each individual. I think there are still many areas of genomic medicine that can be solved by the elementary technologies that Masaru specializes in. Therefore, I would like to see the company actively integrating technological innovations that will have a ripple effect on genomic medicine.

Masaru: I would like to use my expertise in AI technology and apply it to medicine, an area where I can make a significant contribution to society, to help treat patients. As a researcher, I believe it’s important to imagine what I’m trying to achieve in the future while striving to develop the technology at hand. I believe that creating a society in which people can live healthy, prosperous and enjoyable lives is where technology should come into its own.

We want to fully deploy this system and contribute to the well-being of as many people as possible by creating a stress-free environment where information is effectively integrated.

Disclaimer

Fujitsu Ltd. published this content on June 24, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on Jun 24, 2022 01:35:07 UTC.

Comments are closed.